Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
An. bras. dermatol ; 94(3): 341-343, May-June 2019. graf
Article in English | LILACS | ID: biblio-1011101

ABSTRACT

Abstract: CHILD syndrome (Congenital Hemidysplasia, Ichthyosiform erythroderma, Limb Defects) is a rare X-linked dominant disease. The authors report a 2-month-old patient presenting with typical features of CHILD syndrome that was treated with a topical solution containing cholesterol and lovastatin, with complete clearance of her CHILD nevus. The changes in skin lipid metabolism that explain the CHILD ichthyosiform nevus and their correction through topical application of cholesterol and lovastatin are discussed.


Subject(s)
Humans , Female , Infant , Abnormalities, Multiple/drug therapy , Lovastatin/administration & dosage , Cholesterol/metabolism , Ichthyosiform Erythroderma, Congenital/drug therapy , Limb Deformities, Congenital/drug therapy , Genetic Diseases, X-Linked/drug therapy , Anticholesteremic Agents/administration & dosage , Abnormalities, Multiple/genetics , Cholesterol/biosynthesis , Administration, Topical , Ichthyosiform Erythroderma, Congenital/genetics , Limb Deformities, Congenital/genetics , Genetic Diseases, X-Linked/genetics , Metabolic Diseases/genetics
2.
Medicina (B.Aires) ; 76(2): 65-70, abr. 2016. tab
Article in Spanish | LILACS | ID: biblio-841544

ABSTRACT

La agammaglobulinemia ligada al cromosoma X (XLA) se caracteriza por la ausencia o reducción significativa de linfocitos B, niveles bajos o indetectables de inmunoglobulinas y, clínicamente, por infecciones principalmente respiratorias por bacterias capsuladas extracelulares y diarrea recurrente. El tratamiento de reemplazo con gammaglobulina ha permitido a la mayor parte de los enfermos llegar a adultos con una buena calidad de vida. Analizamos las características clínicas de 14 pacientes mayores de 18 años con diagnóstico de XLA asistidos en nuestra Unidad desde 2003, fecha en que fue derivado el primer paciente, hasta 2015. La edad promedio en el momento de la derivación fue de 20.4 años, en el momento de la última consulta de 25.5. El tiempo promedio de seguimiento fue de 59.8 meses. Previo al diagnóstico todos habían presentado infecciones, las más frecuentes fueron las respiratorias. Posteriormente al diagnóstico todos iniciaron tratamiento de reemplazo con gammaglobulina endovenosa, y a pesar de que las infecciones disminuyeron en frecuencia y gravedad, en este período se presentaron enfermedades con secuelas graves. Al comenzar el seguimiento en nuestra Unidad, 35.7% presentaban deterioro de la función respiratoria, solo grave en un paciente. Durante el seguimiento ninguno presentó deterioro de la función respiratoria ni complicaciones clínicas importantes. Tres pasaron a gammaglobulina subcutánea con buena tolerancia. El número de adultos con XLA es cada vez mayor, la mayoría llegan a la segunda década de la vida sin complicaciones graves y bajo tratamiento se mantienen libres de enfermedades infecciosas graves y de progresión de sus secuelas pulmonares.


X-linked agammaglobulinemia (XLA) is characterized by absent or severely reduced B cells, low or undetectable immunoglobulin levels and clinically by extracellular bacterial infections which mainly compromise the respiratory tract as well as recurrent diarrheas. The mainstay of treatment is gammaglobulin replacement therapy, which allows most patients to reach adulthood with high quality of life. We analyzed the clinical features of 14 patients over 18 years of age with XLA diagnosis that received treatment in our unit from the year 2003, the date the first patient was derived, until 2015. The average age at which patients were referred was 20.4 years old; age at the last consult was 25.5. The average follow-up time was 59.8 months. Previously to being diagnosed all patients had suffered infections, most frequently respiratory. After diagnosis all were started on intravenous gammaglobulin replacement treatment and in spite of infections being reduced in severity and frequency, there were cases of severe disease with long term sequelae. At the beginning of our follow-up 35.7% presented impaired respiratory function with only one case being severe. In no cases during this period did the respiratory function worsen, nor were there severe clinical complications. Three patients were switched to subcutaneous immunoglobulin treatment with good tolerance. The number of XLA cases is increasing, as most reach the second decade of life without serious complications and remain free of severe infectious disease and further impairment of their respiratory functions with the treatment.


Subject(s)
Humans , Male , Adult , Young Adult , Immunoglobulins, Intravenous/administration & dosage , Disease Progression , Agammaglobulinemia/complications , Agammaglobulinemia/drug therapy , Genetic Diseases, X-Linked/complications , Genetic Diseases, X-Linked/drug therapy , Quality of Life , Respiratory Tract Infections/etiology , Administration, Cutaneous , gamma-Globulins/administration & dosage , Retrospective Studies , Follow-Up Studies , Administration, Intravenous
3.
Rev. Inst. Med. Trop. Säo Paulo ; 57(5): 455-457, Sept.-Oct. 2015. tab, graf
Article in English | LILACS | ID: lil-766280

ABSTRACT

SUMMARY We describe the case of an eight-year-old boy with X-linked agammaglobulinemia who developed mild varicella despite regular intravenous immunoglobulin (IVIG) therapy. He maintained protective antibody levels against varicella and the previous batches of IVIG that he received had adequate varicella-specific IgG levels. The case illustrates that IVIG may not prevent VZV infection.


RESUMO Relatamos o caso de uma criança com agamaglobulinemia ligada ao X, sexo masculino, oito anos de idade, que desenvolveu quadro de varicela leve, apesar do tratamento regular com imunoglobulina intravenosa (IVIG). O paciente mantinha níveis adequados de imunoglobulina (IgG) contra varicela, assim como, os últimos lotes de IVIG por ele recebido também apresentavam níveis adequados do anticorpo específico. O caso ilustra que o tratamento regular com IVIG não é suficiente para prevenir a infecção pelo vírus da varicela-zoster.


Subject(s)
Child , Humans , Male , Agammaglobulinemia/immunology , Antibodies, Viral/blood , Chickenpox/diagnosis , Genetic Diseases, X-Linked/immunology , /immunology , Immune Sera/administration & dosage , Immunoglobulin G/blood , Agammaglobulinemia/drug therapy , Chickenpox/immunology , Chickenpox/prevention & control , Genetic Diseases, X-Linked/drug therapy , Treatment Failure
4.
Journal of Korean Medical Science ; : 1650-1656, 2013.
Article in English | WPRIM | ID: wpr-148462

ABSTRACT

Congenital adrenal insufficiency is caused by specific genetic mutations. Early suspicion and definite diagnosis are crucial because the disease can precipitate a life-threatening hypovolemic shock without prompt treatment. This study was designed to understand the clinical manifestations including growth patterns and to find the usefulness of ACTH stimulation test. Sixteen patients with confirmed genotyping were subdivided into three groups according to the genetic study results: congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH, n=11), congenital lipoid adrenal hyperplasia (n=3) and X-linked adrenal hypoplasia congenita (n=2). Bone age advancement was prominent in patients with CAH especially after 60 months of chronologic age (n=6, 67%). They were diagnosed in older ages in group with bone age advancement (P<0.05). Comorbid conditions such as obesity, mental retardation, and central precocious puberty were also prominent in this group. In conclusion, this study showed the importance of understanding the clinical symptoms as well as genetic analysis for early diagnosis and management of congenital adrenal insufficiency. ACTH stimulation test played an important role to support the diagnosis and serum 17-hydroxyprogesterone levels were significantly elevated in all of the CAH patients. The test will be important for monitoring growth and puberty during follow up of patients with congenital adrenal insufficiency.


Subject(s)
Adolescent , Child , Child, Preschool , Female , Humans , Male , 17-alpha-Hydroxyprogesterone/blood , Disorder of Sex Development, 46,XY/drug therapy , Adrenal Hyperplasia, Congenital/drug therapy , Adrenal Insufficiency/congenital , Adrenocorticotropic Hormone/metabolism , Bone Development/genetics , DAX-1 Orphan Nuclear Receptor/genetics , Genetic Diseases, X-Linked/drug therapy , Genotype , Glucocorticoids/therapeutic use , Intellectual Disability/complications , Mineralocorticoids/therapeutic use , Obesity/complications , Phosphoproteins/genetics , Puberty, Precocious/complications , Retrospective Studies , Steroid 21-Hydroxylase/genetics
5.
J. bras. nefrol ; 34(1): 78-81, jan.-fev.-mar. 2012. ilus, graf, tab
Article in English | LILACS | ID: lil-623359

ABSTRACT

A doença de Dent é uma tubulopatia ligada ao X causada por mutações no gene que codifica o canal de cloro CLCN-5 e é caracterizada por proteinúria de baixo peso molecular, hipercalciúria, nefrocalcinose e insuficiência renal. Vários casos têm sido descritos, nos quais o único sintoma na apresentação foi proteinúria assintomática e glomerulosclerose global ou segmentar. A insuficiência renal nesses pacientes pode ser causada pela hipercalciúria e proteinúria persistente. Portanto, o inibidor da enzima de conversão da angiotensina e os tiazídicos poderiam ser úteis. O objetivo desta pesquisa é relatar os efeitos destas drogas em dois pacientes com doença de Dent tipo 1 com mutações novas. Neste relato não foram observadas correlações significativas entre dose de hidroclorotiazida e calciúria e entre enalapril e proteinúria. Este achado é importante, pois, sendo pacientes poliúricos, o uso destas drogas poderia prejudicar a função renal.


Dent's disease type 1 is an X-linked tubular disease caused by mutations in the renal chloride channel CLCN-5, and it is characterized by low molecular weight proteinuria, hypercalciuria, nephrocalcinosis, and renal failure. Several cases have been described in which the only presenting symptoms were asymptomatic proteinuria, and focal segmental or global glomerulosclerosis. The renal failure in these patients may be caused by hypercalciuria and persistent proteinuria. Therefore, angiotensin converse enzyme inhibitor and thiazides could be useful. Our aim is to report the effects of these drugs in two novel mutations patients with Dent's disease type 1. In this report, no significant correlations between dosage of hydrochlorothiazide and calciuria and no significant correlations between proteinuria and dosage of enalapril were detected. This is important since these are polyuric patients and these drugs could be dangerous to their renal function.


Subject(s)
Child , Child, Preschool , Humans , Male , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Enalapril/administration & dosage , Genetic Diseases, X-Linked/drug therapy , Genetic Diseases, X-Linked/genetics , Hydrochlorothiazide/administration & dosage , Nephrolithiasis/drug therapy , Nephrolithiasis/genetics , Mutation , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL